Pan-Amyloid Oligomer Specific scFv Antibody Attenuates Memory Deficits and Brain Amyloid Burden in Mice with Alzheimer's Disease

Current Alzheimer Research

Volumn 11, Issue 1, 2014, Pages 69-78

  Zhao, Min ^a,b   Wang, Shao wei ^a,c   Wang, Yu jiong ^c   Zhang, Ran ^a,c   Li, Ya nan ^a   Su, Ya jing ^a   Zhou, Wei wei ^a   Yu, Xiao lin ^a   Liu, Rui tian ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b Tsinghua University   (China)

^c NINGXIA UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid; Immunotherapy; Memory deficit; Oligomer; Single chain variable fragment (scFv) antibody

Indexed keywords

AMYLOID BETA PROTEIN; HEAT SHOCK PROTEIN; OLIGOMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY W20; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CELL LINE, TUMOR; CELL MEMBRANE; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESENILIN-1; SINGLE-CHAIN ANTIBODIES;

EID: 84891795977     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113106660176     Document Type: Article

References (47)

1. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35: 352-358 (2009).
2. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alphasynuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37: 583-595 (2003).
3. Lupi O, Peryassu MA. An emerging concept of prion infections as a form of transmissible cerebral amyloidosis. Prion 1: 223-227 (2007).
4. Iuchi S, Hoffner G, Verbeke P, Djian P, Green H. Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proc Natl Acad Sci USA 100: 2409-2414 (2003).
5. Gurlo T, Ryazantsev S, Huang CJ, Yeh MW, Reber HA, Hines OJ, et al. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol 176: 861-869 (2010).
6. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408(6815): 982- 985 (2000).
7. Delrieu J, Ousset PJ, Caillaud C, Vellas B. 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 120(1): 186-93 (2012).
8. Schnabel J. Vaccines: chasing the dream. Nature 475: S18-S19 (2011).
9. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2: 18 (2007).
10. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, et al. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284: 4230-4237 (2009).
11. Zhang X, Sun XX, Xue D, Liu DG, Hu XY, Zhao M, et al. Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses. Biochim Biophys Acta 1814: 1703-1712 (2011).
12. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489 (2003).
13. Du XT, Wang L, Wang YJ, Andreasen M, Zhan DW, Feng Y, et al. Abeta1-16 Can Aggregate and Induce the Production of Reactive Oxygen Species, Nitric Oxide, and Inflammatory Cytokines. J Alzheimers Dis 27: 401-413 (2011).
14. Wang XP, Zhang JH, Wang YJ, Feng Y, Zhang X, Sun XX, et al. Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS Lett 583: 579-584 (2009).
15. Yoshiike Y, Minai R, Matsuo Y, Chen YR, Kimura T, Takashima A. Amyloid oligomer conformation in a group of natively folded proteins. PLoS One 3: e3235 (2008).
16. Yang SG, Zhang X, Sun XS, Ling TJ, Feng Y, Du XY, et al. Diverse ecdysterones show different effects on amyloid-beta42 aggregation but all uniformly inhibit amyloid-beta42-induced cytotoxicity. J Alzheimers Dis 22: 107-117 (2010).
17. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, et al. Certain inhibitors of synthetic amyloid betapeptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 25: 2455-2462 (2005).
18. Haley TJ, McCormick WG. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12: 12-15 (1957).
19. Janusz M, Woszczyna M, Lisowski M, Kubis A, Macala J, Gotszalk T, et al. Ovine colostrum nanopeptide affects amyloid beta aggregation. FEBS Lett 583: 190-196 (2009).
20. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1: 848-858 (2006).
21. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid betapeptide. Nat Rev Mol Cell Biol 8: 101-112 (2007).
22. Stefani M. Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. FEBS J 277: 4602-4613 (2010).
23. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid {beta}-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA 108: 5819-5824 (2011).
24. Takamura A, Okamoto Y, Kawarabayashi T, Yokoseki T, Shibata M, Mouri A, et al. Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse. Mol Neurodegener 6: 20 (2011).
25. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400: 173-177 (1999).
26. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562 (2005).
27. Fukuchi K, Accavitti-Loper MA, Kim HD, Tahara K, Cao Y, Lewis TL, et al. Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. Biochem Biophys Res Commun 344: 79-86 (2006).
28. Liu R, Yuan B, Emadi S, Zameer A, Schulz P, McAllister C, et al. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43: 6959-6967 (2004).
29. Marin-Argany M, Rivera-Hernandez G, Marti J, Villegas S. An anti-Abeta (amyloid beta) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Abeta oligomers from the amyloid pathway. Biochem J 437: 25-34 (2011).
30. Ryan DA, Mastrangelo MA, Narrow WC, Sullivan MA, Federoff HJ, Bowers WJ. Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol Ther 18: 1471-1481 (2010).
31. Wang YJ, Gao CY, Yang M, Liu XH, Sun Y, Pollard A, et al. Intramuscular delivery of a single chain antibody gene prevents brain Abeta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun 24: 1281-1293 (2010).
32. Morley JE, Farr SA, Banks WA, Johnson SN, Yamada KA, Xu L. A physiological role for amyloid-beta protein:enhancement of learning and memory. J Alzheimers Dis 19: 441-449 (2010).
33. Parihar MS, Brewer GJ. Amyloid-beta as a modulator of synaptic plasticity. J Alzheimers Dis 22: 741-763 (2010).
34. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci USA 106: 12145-12150 (2009).
35. O'Nuallain B, Williams AD, McWilliams-Koeppen HP, Acero L, Weber A, Ehrlich H, et al. Anti-amyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol 30 (1): S37-42 (2010).
36. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30: 1728-1736 (2009).
37. O'Nuallain B, Acero L, Williams AD, Koeppen HP, Weber A, Schwarz HP, et al. Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 47: 12254-12256 (2008).
38. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 7: 90 (2010).
39. Goni F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, et al. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One 5: e13391 (2010).
40. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451: 720-724 (2008).
41. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Muller R, Nimmrich V, et al. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 30: 10369-10379 (2010).
42. Zhang Y, He JS, Wang X, Wang J, Bao FX, Pang SY, et al. Administration of amyloid-beta42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice. J Alzheimers Dis 23: 551-561 (2011).
43. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta In vivo by immunotherapy. J Neurosci 22: 7873-7878 (2002).
44. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci USA 106: 14745-14750 (2009).
45. Schmitt E, Gehrmann M, Brunet M, Multhoff G C. Garrido. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leuko Biol 81: 15-27 (2007).
46. Stetler RA, Gan Y, Zhang W, Liou AK, Gao Y, Cao G, et al. Heat shock proteins: cellular and molecular mechanisms in the central nervous system. Prog Neurobiol 92: 184-211 (2010).
47. Calderwood SK, Mambula SS, Gray PJ, Jr., Theriault JR. Extracellular heat shock proteins in cell signaling. FEBS Lett 581: 3689-3694 (2007).